Serghei Popa

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

Sophie Glatt, Dominique Baeten, Terry Baker et al. · Annals of the Rheumatic Diseases · 2017 · 259 citations · Full text

Medicine, Immunology, Pharmacology +17

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

Daniel J. Wallace, Vibeke Strand, Joan T. Merrill et al. · Annals of the Rheumatic Diseases · 2016 · 133 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin

Daniel Tatosian, Ying Guo, Andrea Schaeffer et al. · Diabetes Therapy · 2013 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

Jeremy D. Gale, Brian B. Berger, Steven A. Gilbert et al. · Investigative Ophthalmology & Visual Science · 2018 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects

Walter Krauwinkel, Jan Noukens, Jan van Dijk et al. · Journal of Clinical Pharmacy and Therapeutics · 2017 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15